Zacks
Do Options Traders Know Something About Delcath Systems Stock We Don't?
➖
AI Sentiment
Neutral
5/10
- Home
- DCTH
DCTH
Delcath Systems Inc.
as of 11-28-2025 12:38pm EST
$9.69
+$0.05
+0.50%
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
Chart Type:
Time Range:
| Founded: | 1988 | Country: | United States |
| Employees: | N/A | City: | QUEENSBURY |
| Market Cap: | 289.2M | IPO Year: | N/A |
| Target Price: | $22.60 | AVG Volume (30 days): | 997.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.03 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.12 - $18.23 | Next Earning Date: | 11-04-2025 |
| Revenue: | $79,603,000 | Revenue Growth: | 251.54% |
| Revenue Growth (this year): | 135.11% | Revenue Growth (next year): | 36.30% |
AI-Powered DCTH Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 73.08%
73.08%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Delcath Systems Inc. (DCTH)
Sylvester John Richard
Buy
Director
DCTH Nov 21, 2025
Avg Cost/Share
$8.89
Shares
4,386
Total Value
$38,991.54
Owned After
14,936
SEC Form 4
MICHEL GERARD J
Buy
CHIEF EXECUTIVE OFFICER
DCTH Nov 11, 2025
Avg Cost/Share
$8.53
Shares
11,500
Total Value
$98,049.00
Owned After
330,834
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Sylvester John Richard | DCTH | Director | Nov 21, 2025 | Buy | $8.89 | 4,386 | $38,991.54 | 14,936 | |
| MICHEL GERARD J | DCTH | CHIEF EXECUTIVE OFFICER | Nov 11, 2025 | Buy | $8.53 | 11,500 | $98,049.00 | 330,834 |
Latest Delcath Systems Inc. News
DCTH Breaking Stock News: Dive into DCTH Ticker-Specific Updates for Smart Investing
Compare DCTH vs Leading Stocks
See how DCTH stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "DCTH Delcath Systems Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.